You are here: Industry Insights > Veklury

News List

EC expands indication for Gilead’s Veklury to treat Covid-19 patients Pharmaceutical-Technology
December 23, 2021
The European Commission (EC) has granted approval to the Conditional Marketing Authorization (CMA) variation for Gilead Sciences’ antiviral Veklury (remdesivir) to include adult Covid-19 patients...
Veklury Drives 2Q Growth for Gilead contractpharma
August 02, 2021
Veklury (remdesivir) with sales of $829 million offsets loss of exclusivity of Truvada and Atripla in the U.S. with sales down 72% and 42%, respectively.
Real-world evidence confirms Veklury® reduces COVID-19 mortality europeanpharmaceuticalreview
June 23, 2021
New real-world analyses demonstrate Veklury® (remdesivir) reduces mortality and increases likelihood of discharge in hospitalised COVID-19 patients.
Gilead Revenues up 16% in the Quarter contractpharma
May 06, 2021
Veklury drives growth in the quarter, offsetting significant declines in HIV, HCV franchises.
Gilead Sciences to support expansion of local production capacity of Remdesivir in India expresspharma
April 28, 2021
Gilead will donate a minimum of 450,000 vials of Veklury to the Government of India.
FDA Provides Specific Compounded Drug Concerns Related to COVID-19 americanpharmaceuticalreview
February 26, 2021
The U.S. Food and Drug Administration (FDA) is advising compounders and health care providers the agency has concerns about the use of certain drugs prepared by compounders to treat patients with COVID-19.
February Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights europeanpharmaceuticalreview
February 19, 2021
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) began two new reviews and wrote guidance for healthcare professionals on the potential side effects of Strimvelis, Venclyxto and Zolgensma.
Gilead 4Q Revenues up 26% contractpharma
February 10, 2021
Revenue growth for the quarter and full year was primarily due to the launch of Veklury (remdesivir).
FDA Announces Alert of Potential Risks Associated with Compounding of Remdesivir americanpharmaceuticalreview
February 08, 2021
The U.S. Food and Drug Administration (FDA) approved a new drug application (NDA) for Veklury (remdesivir), a drug indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of COVID-19 ...
Gilead's Veklury should be effective against COVID-19 variants pharmatimes
January 25, 2021
Gilead Sciences has released a statement regarding the efficacy of its antiviral treatment Veklury (remdesivir), maintaining confidence in the its continued benefit against new COVID-19 variants.

Previous page 1 2 3 Next page